Nuvectis Reports 40% Response Rate for NXP200 in Phase 1b High-Grade Glioma Study

• Nuvectis Pharma reported positive Phase 1b results for NXP200, already presented at the 2026 European Society for Medical Oncology Congress.
• Treatment produced durable responses, including complete responses, in recurrent or progressive BRAF V600-mutated gliomas. Some patients previously treated with BRAF inhibitors responded.
• NXP200 showed a manageable safety profile. No treatment-related adverse event led to discontinuation or death.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260830PRIMZONEFULLFEED9852939) on October 26, 2026, and is solely responsible for the information contained therein.